The 2022 American Association for Cancer Research (AACR) Annual Meeting represents the first major in-person oncology industry event in more than years and George Clinical invites you to engage our scientific leaders, clinical operations experts and business development team to schedule formal briefings or informal meetings at our exhibit (#1052). Oncologists Dr. Ari VanderWalde, a long-standing George Clinical scientific leader, and Professor David Thomas from partner organization OMICO will both be in attendance
AACR runs from April 8–13 in New Orleans, Louisiana with exhibition hours daily from April 10–13. The AACR Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; the AACR Annual Meeting highlights the work of the best minds in cancer research from institutions all over the world.
Dr. Thomas’ focus is on the application of genomic technologies to the understanding and management of cancer. He is Head of the Genomic Cancer Medicine Laboratory at the Garvan Institute of Medical Research, and a National Health & Medical Research Council (NHMRC) L3 Investigator. He is CEO of Omicron, a non-profit company with a national precision medicine program for patients with advanced and early onset cancers, which he established in 2019. He is also Conjoint Professor, UNSW, Sydney.
Dr. Thomas is an internationally recognized leader in his field and is especially interested in precision oncology and clinical trials, somatic and germline cancer genomics, and sarcomas and cancer in young adults. He founded the Australasian Sarcoma Study Group, a national research organization, and established Australia’s leading adolescent and young adult cancer unit at the Peter MacCallum Cancer Centre. He leads the International Sarcoma Kindred Study, and led the first international study of denosumab in Giant Cell Tumor of bone, leading to FDA and TGA approval. In 2018, he was President of the Connective Tissue Oncology Society, the peak international body in his field.
Dr. VanderWalde’s primary research is in melanoma, immunotherapy and targeted therapies based on immune markers and aberrations in cancer genetics. He is Vice President of Clinical Development, Caris Life Sciences, and Senior Medical Director, George Clinical. A thought leader in melanoma and clinical trial design and implementation, he has collaborated on advisory boards with many of the nation’s thought leaders and top experts in the field and previously served as United States Medical Lead and Clinical Research Medical Director with Amgen Inc., directing U.S. global development of talimogene laherparepvec, a novel viral-based immunotherapeutic that has shown efficacy in late-stage clinical trials in melanoma.
As Former Director of Research at West Cancer Center and Research Institute, Dr. VanderWalde was responsible for managing the portfolio of all clinical trials. He is the former Director of Precision Oncology at OneOncology.
Ernest N. Morial Convention Center
900 Convention Center Blvd
New Orleans, LA
Meet with George Clinical! Contact us to schedule a time now.